Literature DB >> 2755859

Effects of controlled-released morphine on quality of life for cancer pain.

B Ferrell, C Wisdom, C Wenzl, J Brown.   

Abstract

Oncology nursing is concerned with pain relief and overall Quality of Life (QOL). The purpose of this study was to determine the effects of controlled-release morphine on QOL for patients with cancer. Eighty-three subjects were randomly assigned in a clinical trial of short-acting versus controlled-release analgesia (MS Contin, Purdue Frederick Co., Norwalk, CT). Data was collected in a repeated measures design every 2 weeks for 6 weeks yielding a total of 240 visits. Five instruments were used to assess QOL, pain, and functional status. Study findings indicate improved pain management with controlled-release MS Contin and important nursing implications for the management of analgesia-induced gastrointestinal symptoms. Through appropriate pain management with pain therapies such as controlled-release analgesia, nurses can greatly enhance QOL for the patient with cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2755859

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  18 in total

Review 1.  Nursing research into quality of life.

Authors:  G V Padilla; M M Grant; B Ferrell
Journal:  Qual Life Res       Date:  1992-10       Impact factor: 4.147

Review 2.  A comparison of long- and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs.

Authors:  Charles E Argoff; Daniel I Silvershein
Journal:  Mayo Clin Proc       Date:  2009-07       Impact factor: 7.616

Review 3.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-22

Review 4.  Quality of life measures in cancer chemotherapy: methodology and implications.

Authors:  P A Ganz
Journal:  Pharmacoeconomics       Date:  1994-05       Impact factor: 4.981

Review 5.  Pharmacoeconomics of chronic nonmalignant pain.

Authors:  M J Zagari; P D Mazonson; W C Longton
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

6.  Translating safety, efficacy and compliance into economic value for controlled release dosage forms.

Authors:  M P Cramer; S R Saks
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

Review 7.  Opioid analgesics: comparative features and prescribing guidelines.

Authors:  N I Cherny
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

8.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

Review 9.  [Differential therapeutic aspects of analgesia with oral sustained-release strong opioids: application intervals, metabolism and immunosuppression].

Authors:  K Güttler; R Sabatowski
Journal:  Schmerz       Date:  2008-10       Impact factor: 1.107

Review 10.  Clinical use of opioids for cancer pain.

Authors:  Dermot R Fitzgibbon
Journal:  Curr Pain Headache Rep       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.